The McClay Foundation Competitors and Similar CompaniesClear all

The McClay Foundation's competitors and similar companies include 4SC, BioNTech, Shorla Oncology and Noviga Research.

	The McClay Foundation The McClay Foundation is a charitable health organization.	4SC 4SC is a biopharmaceutical company developing small-molecule drugs for the treatment of cancer.	BioNTech BioNTech is a biotechnology company developing immunotherapies for cancer and infectious diseases.	Shorla Oncology Shorla Oncology (also known as Shorla Pharma) is a pharmaceutical company that develops cancer treatment solutions.	Noviga Research Noviga Research is a company developing a cancer treatment medications.
Founding Date	Founding Date 2008	Founding Date 1997	Founding Date 2008	Founding Date 2018	Founding Date 2014
Type	Type Private	Type Public	Type Public	Type Private	Type Private
Tags	Tags Healthcare charity clinical research drug development oncology	Tags Healthcare clinical research drug development oncology	Tags Healthcare clinical research drug development oncology	Tags Healthcare clinical research drug development oncology	Tags Healthcare clinical research drug development oncology
Locations	Locations Craigavon, GB HQ	Locations Planegg, DE HQ	Locations Mainz, DE HQ Melbourne, AU Wien, AT Shanghai, CN Paris, FR Berlin, DE Berlin, DE see more	Locations Clonmel, IE HQ Cambridge, US	Locations Södertälje, SE HQ
Employees	Employees N/A	Employees 13	Employees 6,772	Employees 4914% increase	Employees 3
Valuation ($)	Valuation ($) N/A	Valuation ($) 74 m	Valuation ($) 27.1 b	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €2.6m (FY, 2025)	Revenue (est.) €2.9b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods €45k (FY, 2025)	Cost of goods €260.4m (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €2.5m (FY, 2025)	Gross profit €2.7b (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income (€3.5m) (FY, 2025)	Net income (€1.1b) (FY, 2025)	Net income N/A	Net income N/A